Sandra Strauss is a Senior Clinical Lecturer and Honorary Consultant Medical Oncologist. Her clinical post is based at University College London Hospital, part of the London Sarcoma Service, one of the largest sarcoma services in Europe. She specialises in the systemic treatment of bone and soft tissue sarcomas in both adults and teenagers.

Sandra began training as a medical oncologist working on the adolescent unit at the Middlesex Hospital where she developed an interest in sarcoma and teenage and young adult (TYA) cancer.  She completed a Cancer Research UK Clinical Fellowship to obtain a PhD (University of London) at St Bartholomew's Hospital investigating pre-clinical and clinical effects of novel treatments for cancer, and investigating translational markers to improve their effects. In 2009, she was awarded a Career Development Award from the Sarcoma Alliance for Research through Collaboration (SARC), which allowed her to further her research aiming to identify new targets for the treatment of sarcoma; work that is ongoing in the UCL Cancer Institute. She has a strong interest in translating these findings into benefit for patients and early phase clinical trials, particularly in sarcomas affecting teenagers and young adults.

She is the chief investigator and principle investigator for a number of international and national phase I, II and III studies in sarcoma and  is leading a national cohort study in osteosarcoma, ICONIC. She chairs the NCRI Sarcoma Clinical Studies Group Bone Subgroup and was recently appointed Chair of the Executive Committee of the European EuroEwing consortium (EEC), a pan-European collaboration to improve outcome for patients with Ewing sarcoma. She is a member of the EORTC Soft Tissue and Bone Sarcoma Group and Innovative Therapies for Children with Cancer (ITCC) consortium and is the Clinical lead for Sarcoma and rare cancers for the Public Health England (PHE) National Cancer Registration and Analysis Service (NCRAS). Here, she is particularly interested in understanding variations in patient pathways and access to specialist services to reduce inequalities and improve outcome for patients with rare cancers.